Physician profile
Thomas M Reske
NPI 1669545802
$7,847.30
in general payments reported to CMS, 2019-2025
19 companies · $4,422 in 2025
The $4,422 reported for 2025 was more than what 97% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $351 · 2020: $19.38 · 2022: $2,218 · 2023: $338 · 2024: $498 · 2025: $4,422.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $3,650 · Food and Beverage: $907 · Travel and Lodging: $501 · Honoraria: $200.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $3,650.00 |
| Food and Beverage | $907.39 |
| Travel and Lodging | $500.82 |
| Honoraria | $200.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Partner Therapeutics, INC. | $3,750.01 | 2025 | Bizengri |
| Exelixis INC. | $1,664.14 | 2019-2022 | |
| Daiichi Sankyo INC. | $1,400.00 | 2022-2025 | Vanflyta |
| Stryker Corporation | $154.08 | 2024 | Augment Injectable |
| Tempus Ai, INC | $135.68 | 2024 | |
| Incyte Corporation | $125.00 | 2024 | Monjuvi |
| Pfizer INC. | $111.31 | 2019-2024 | |
| Jazz Pharmaceuticals INC. | $101.62 | 2023 | |
| Novartis Pharmaceuticals Corporation | $70.28 | 2019 | |
| Genzyme Corporation | $62.73 | 2019-2022 | |
| E.R. Squibb & Sons, L.L.C. | $51.14 | 2019 | |
| Merck Sharp & Dohme LLC | $45.14 | 2019 | |
| Amgen INC. | $36.45 | 2019 | |
| Astellas Pharma US INC | $33.28 | 2019-2020 | |
| Lilly USA, LLC | $32.62 | 2019 |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Dendreon Pharmaceuticals LLC | $22.43 | 2025 | Provenge |
| Gilead Sciences, INC. | $19.35 | 2023 | Trodelvy |
| Celgene Corporation | $17.85 | 2019 | |
| Alexion Pharmaceuticals, INC. | $14.19 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Thomas Reske listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.